

Agenda Item: 18.45c

Subject:	<p>i) Prescribing and medicines optimisation quarterly update</p> <p>ii) Summary of recommendations of the Norfolk & Waveney Therapeutics Advisory Group (TAG) and related Commissioning Decisions by the Norfolk & Waveney CCGs' Drugs & Therapeutics Commissioning Group (D&TCG) – May 2013 to November 2017</p>
Presented by:	Sarah Jane Ward
Submitted to:	Governing Body
Purpose of Paper:	Quarterly update outlining West Norfolk Prescribing Information
<p>Prescribing and medicines optimisation quarterly update</p> <p>The attached report of 3rd April 2018 by ArdenGEM CSU covers areas of prescribing namely antibiotics, controlled drugs and medicines' safety as well as giving a performance summary.</p> <p>Update in regards to report:</p> <p>Flu vaccines- cost pressure is resolved and NHS England are working with CCGs in switching budget to them.</p> <p>Antimicrobial Stewardship: The CCG is working with colleague sin NHSi, Public Health to re-promote guidance and support in regards to this agenda. With a Norfolk wide study day planned for 9th & 10th of July in 2 venues, one specifically in the West.</p> <p>West Norfolk is a high prescriber of antibiotics and showing as an outlier.</p> <p>More information on the strategy for West Norfolk will be shared at the next governing body.</p> <p>Summary of recommendations of the Norfolk & Waveney Therapeutics Advisory Group (TAG) and related Commissioning Decisions by the Norfolk & Waveney CCGs' Drugs & Therapeutics Commissioning Group (D&TCG) – May 2013 to November 2017 The report outlines the decisions made from May 2013 to November 2017. The report s to ensure the governing bodies are sighted of all the decisions made in this time frame</p>	
KEY RISKS (in relation to CCG strategic objectives and statutory duties)	
Clinical & Quality: Reduction in use of antimicrobial medications, potential issues of antimicrobial resistance and increase in <i>c.difficile</i> cases	
Finance and Performance: Outlier in antibiotic prescribing	
Reputation: Potential	

Legal: nil
Patient focus: Patient experience
Information Governance: Nil
Conflicts of Interest: potential as clinicians of governing Body are prescribers
Equality Impact Assessment: N/a
Reference to relevant risk on the Governing Body Assurance Framework:
RECOMMENDATION: To note the report